Sawai Ends American Dream With Upsher-Smith Sale
Bora Strikes $210m Deal For US Unit; Sawai Cites Buyer Consolidation And Indian Competition
Japanese generics giant Sawai is pulling out of the US market, agreeing a deal to divest its Upsher-Smith business to Taiwan’s Bora Pharmaceuticals in a deal worth a little over $200m. As Sawai explained its rationale for the move, Bora pointed to “significant opportunities” for its TWi commercial prescription unit arising from the acquisition.
